Baricitinib: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Dosing== |
==Dosing== |
||
* 4 mg p.o. daily for 14 days, or until hospital discharge |
* Severe or critical [[COVID-19]]: 4 mg p.o. daily for 14 days, or until hospital discharge |
||
===Renal Dosing=== |
===Renal Dosing=== |
||
* eGFR 30-60 mL/min: 2 mg p.o. daily |
* eGFR 30-60 mL/min: 2 mg p.o. daily |
||
* eGFR 15-30 mL/min: 1 mg p.o. daily |
* eGFR 15-30 mL/min: 2 mg p.o. every other day, or 1 mg p.o. daily |
||
* eGFR less than 15 mL/min: not recommended |
|||
* Dialysis: not recommended |
|||
== Safety == |
== Safety == |
||
| Line 14: | Line 16: | ||
=== Contraindications === |
=== Contraindications === |
||
* Contraindications and relative contraindications include hypersensitivity, co-existing infection, immunosuppression, increase liver enzymes |
* Contraindications and relative contraindications include hypersensitivity, co-existing infection, immunosuppression, increase liver enzymes |
||
=== Adverse Reactions === |
|||
* Increased risk of infections |
|||
* Venous thrombosis and thromboembolism |
|||
[[Category:Medications]] |
[[Category:Medications]] |
||
Latest revision as of 14:54, 6 May 2025
Background
- Oral JAK inhibitor
- Indications include COVID-19
Dosing
- Severe or critical COVID-19: 4 mg p.o. daily for 14 days, or until hospital discharge
Renal Dosing
- eGFR 30-60 mL/min: 2 mg p.o. daily
- eGFR 15-30 mL/min: 2 mg p.o. every other day, or 1 mg p.o. daily
- eGFR less than 15 mL/min: not recommended
- Dialysis: not recommended
Safety
Contraindications
- Contraindications and relative contraindications include hypersensitivity, co-existing infection, immunosuppression, increase liver enzymes
Adverse Reactions
- Increased risk of infections
- Venous thrombosis and thromboembolism
